Idris I, Patiag D, Gray S, Donnelly R
Compounded semaglutide has grown in popularity during shortages, but compounded drugs are not approved by the Food and Drug Administration (FDA)
Retatrutide's cardiovascular trial: TRIUMPH-Outcomes is ongoing, enrolling patients with obesity and established cardiovascular disease
All UK pharmacies and prescribers must be properly regulated (GPhC, GMC, CQC registered)
GLP-1R agonists may exert antidepressant effects by modulating inflammatory processes in the brain Chronic inflammatory processes in the brain associated with excessive activation of microglia and increased production of pro-inflammatory cytokines are one of the key factors leading to the development of depressive symptoms, as patients suffering from this mental illness are very often characterized by elevated levels of tumor necrosis factor-alpha (TNF-), interleukin-6 (IL-6), interleukin-1 beta (IL-1), C-reactive protein (CRP), and interferon-gamma (IFN-) in the cerebrospinal fluid and the blood [59,60,61]